Spread awareness by sharing and learning more. Post the social media graphic, sign up for a conference, March for Marrow, and AAMDSIF Global PNH Patient Registry! Learn more about PNH.
Paroxysmal Nocturnal Hemoglobinuria (PNH) Donate to Support Our Mission
Ravulizumab, a second-generation complement component 5 inhibitor (C5i) derived from eculizumab eculizumab:
CONFERENCE LOCATION:
Heldrich Hotel
10 Livingston Avenue
New Brunswick, NJ 08901
Parking:
Complimentary hotel valet parking
Abstract 6508 Background: Advances in hematopoietic stem cell transplantation (HSCT) have been driven by progress in supportive care, conditioning regimens, and graft-versus-host disease (GvHD) prophylaxis. Post-transplant morbidity and mortality are most pronounced in the first…
Haploidentical bone marrow transplantation (haplo-BMT) with post-transplant cyclophosphamide (PT-Cy) has become an established alternative for patients lacking HLA-matched donors, with outcomes comparable to those of matched-sibling and unrelated-donor transplants [1]. While CD34…
Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) clones are detected in up to 60% of patients with aplastic anemia (AA); however, their prognostic impact remains incompletely defined, particularly in the context of frontline immunosuppressive therapy (IST) or…
Abstract Objective: To evaluate the efficacy and prognostic factors of haploidentical haematopoietic stem cell transplantation (haplo-HSCT) for paroxysmal nocturnal haemoglobinuria (PNH). Methods: We retrospectively analyzed 36 PNH patients (2 classic PNH, 34 AA-PNH syndrome)…
Abstract Purpose of Review In inherited bone marrow failure syndromes (IBMFS), clonal hematopoiesis (CH) has been increasingly recognized as a molecular fingerprint of the underlying pathophysiology. A specific clonal profile has been reported in telomere biology disorders (TBDs)…
